Acumen pharmaceuticals to present deeper insights from first-in-human phase 1 study of acu193 for early alzheimer's during symposium at the 16th annual clinical trials on alzheimer's disease (ctad)

Charlottesville, va. and indianapolis, oct. 04, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today announced that it will present deeper insights and new exploratory findings from its phase 1 intercept-ad trial evaluating acu193, the first clinical-stage aΒo-directed antibody therapy for early ad, at the 16th annual clinical trials on alzheimer's disease (ctad) conference taking place in boston and online from october 24-27, 2023. intercept-ad was selected to be featured in a symposium on friday, october 27, and data from exploratory analyses of the phase 1 trial will also be shared in two in-person and two virtual poster presentations.
ABOS Ratings Summary
Quant
ABOS Quant Ranking
Sector
Industry
Quant Rating
Quant Score